News
-
-
PRESS RELEASE
ReelTime's RI Unlocks 2.8 Billion-Device Market Allowing Android Users Worldwide Reel Intelligence Without App Store Restrictions with Direct Deployment Skipping Google Play Store
ReelTime's Reel Intelligence 'RI' achieves direct installation on 2.8 billion Android devices worldwide, offering next-gen AI capabilities. No app store required, creating a new era in AI access and distribution -
-
PRESS RELEASE
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma
Xenetic Biosciences collaborates with PeriNess for an exploratory clinical study of DNase I with anti-CD19 CAR T cells in large B cell lymphoma patients at Tel Aviv Sourasky Medical Center -
PRESS RELEASE
FRP Holdings, Inc. Announces Release Date for Its 2025 Second Quarter Earnings and Details for the Earnings Conference Call
FRP Holdings, Inc. (NASDAQ: FRPH) to release Q2 earnings on August 6, 2025, with a conference call on August 7, 2025. Details for access provided. Company involved in real estate business -
PRESS RELEASE
Safe & Green Holdings Restructures Recent Transaction, Reducing Dilution and Complies with NASDAQ Panel Requirements
Safe & Green Holdings Corp. restructures private placement with D. Boral Capital, cancelling Series A and Series B Warrants to reduce dilution by 70%. Complies with NASDAQ standards -
-
-
PRESS RELEASE
Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
NanoViricides introduces drug candidate NV-387 as a potential treatment for Measles outbreak. The drug has shown safety and effectiveness in animal studies and Phase I trial, aiming to combat the global epidemic -
